Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer

From December 1994 to July 1997, we conducted a dose escalation study of irinotecan combined with carboplatin in 17 patients with advanced non-small-cell lung cancer (NSCLC) to determine the maximum tolerated dose and the dose-limiting toxicities. Irinotecan was administered intravenously over 90 mi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2001-08, Vol.48 (2), p.104-108
Main Authors: TAKEDA, Koji, NEGORO, Shunichi, TAKIFUJI, Nobuhide, NITTA, Takashi, YOSHIMURA, Naruo, TERAKAWA, Kazuhiko, FUKUOKA, Masahiro
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Camptothecin - administration & dosage
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Carboplatin - administration & dosage
Carboplatin - adverse effects
Carcinoma, Non-Small-Cell Lung - drug therapy
Chemotherapy
Dose-Response Relationship, Drug
Female
Hematologic Diseases - chemically induced
Humans
Irinotecan
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:From December 1994 to July 1997, we conducted a dose escalation study of irinotecan combined with carboplatin in 17 patients with advanced non-small-cell lung cancer (NSCLC) to determine the maximum tolerated dose and the dose-limiting toxicities. Irinotecan was administered intravenously over 90 min on days 1, 8 and 15, with carboplatin given at an area under the concentration-time curve dose of 5 mg/ml x min (calculated using Calvert's formula) on day 1. The starting dose of irinotecan was 30 mg/m2 and dose escalation was done in 10-mg/m2 increments. Treatment was repeated at 28-day intervals for at least two cycles. The dose-limiting toxicities were neutropenia and thrombocytopenia, since three out of five patients given 60 mg/m2 of irinotecan developed grade 4 neutropenia and thrombocytopenia. The overall response rate was 35.3%. The median survival time and the 1-year survival rate were 10.5 months and 35.3%, respectively. The maximum tolerated dose of irinotecan with this regimen was 60 mg/m2, while 50 mg/m2 can be recommended for future use. Further studies of this combination in advanced NSCLC are warranted.
ISSN:0344-5704
1432-0843
DOI:10.1007/s002800100316